RNN Share Price

Open 0.16 Change Price %
High 0.17 1 Day 0.00 0.00
Low 0.16 1 Week -0.01 -5.88
Close 0.16 1 Month 0.00 0.00
Volume 775065 1 Year -0.27 -62.79
52 Week High 0.45
52 Week Low 0.14
RNN Important Levels
Resistance 2 0.17
Resistance 1 0.17
Pivot 0.16
Support 1 0.15
Support 2 0.15
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RBY 0.03 -70.00%
PBTH 8.23 0.37%
SYRG 9.53 1.71%
NGD 3.72 0.27%
NGD 3.72 0.27%
GGR 0.02 100.00%
VTG 0.05 -16.67%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
CMFO 0.06 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
More..

Rexahn Pharmaceuticals, Inc. (AMEX: RNN)

RNN Technical Analysis 4
As on 6th Dec 2016 RNN Share Price closed @ 0.16 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.27 & Sell for SHORT-TERM with Stoploss of 0.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
RNN Target for December
1st Target up-side 0.2
2nd Target up-side 0.23
3rd Target up-side 0.25
1st Target down-side 0.14
2nd Target down-side 0.11
3rd Target down-side 0.09
RNN Other Details
Segment EQ
Market Capital 39568448.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.rexahn.com
RNN Address
RNN
15245 Shady Grove Road
Suite 455
Rockville, MD 20850
United States
Phone: 240-268-5300
Fax: 240-268-5310
Interactive Technical Analysis Chart Rexahn Pharmaceuticals, Inc. ( RNN AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Rexahn Pharmaceuticals, Inc.
RNN Business Profile
Rexahn Pharmaceuticals, Inc., a development stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt, which has completed a Phase IIa clinical trials for the treatment of pancreatic cancer; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action that is in Phase Ib clinical trials for the treatment of solid tumors; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase, which is in Phase I clinical trials for the treatment of solid tumors. The company’s pre-clinical product pipeline consists of RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, an anticancer nano-polymer drug. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries, Ltd.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Ohio State University; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.